Related Experiment Video

Updated: May 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Life after failure of traditional androgen deprivation therapy

Paul Schellhammer1

  • 1Eastern Virginia Medical School, Virginia Beach, VA 23464, USA. schellpf@evms.edu

Urologic Oncology
|July 17, 2012
PubMed

Insights

Castrate-resistant prostate cancer can be treated by targeting androgen synthesis or the androgen receptor. New therapies are being evaluated in clinical trials for advanced prostate cancer patients.

Area of Science:

  • Oncology
  • Urology
  • Endocrinology

Background:

  • Castrate-resistant prostate cancer (CRPC) presents a therapeutic challenge.
  • Traditional medical castration involves androgen deprivation therapy (ADT).
  • Some CRPC cases paradoxically respond to therapies targeting the androgen pathway.

Purpose of the Study:

  • To review novel therapeutic strategies for CRPC.
  • To evaluate the role of new androgen biosynthesis inhibitors and antiandrogens.
  • To explore the potential of parenteral estrogens in advanced prostate cancer treatment.

Main Methods:

  • Review of ongoing phase 3 clinical trials.
  • Analysis of emerging data on androgen pathway inhibitors.
  • Assessment of historical and current research on estrogen therapy.

Main Results:

  • Novel androgen biosynthesis inhibitors and antiandrogens are under investigation in phase 3 trials.
  • These agents aim to treat men with advanced prostate cancer who have progressed on or after standard ADT.
  • Renewed interest in parenteral estrogens suggests a potential role for revisiting earlier treatment modalities.

Conclusions:

  • Targeting androgen synthesis and the androgen receptor remains a viable strategy for CRPC.
  • Ongoing clinical trials will define the precise role of new agents in advanced prostate cancer.
  • Parenteral estrogens may offer a new perspective on initial medical therapy for prostate cancer.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Menopause01:28

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...